aTyr Pharma, Inc.(ATYR)

搜索文档
aTyr Pharma, Inc.(ATYR) - 2025 FY - Earnings Call Presentation
2025-07-03 21:07
A New Approach to Interstitial Lung Disease J.P. Morgan Healthcare Conference Sanjay S. Shukla, M.D., M.S., President and CEO January 16, 2025 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "f ...
aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
Globenewswire· 2025-06-26 20:00
SAN DIEGO, June 26, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the Company is expected to be added to the Russell 2000® Index and broad market Russell 3000® Index, effective after the U.S. market close on June 27, 2025, as part of the 2025 Russell U.S. Indexes annual reconstitution. The Russel ...
aTyr Pharma (ATYR) 2025 Conference Transcript
2025-06-06 03:00
aTyr Pharma (ATYR) 2025 Conference June 05, 2025 02:00 PM ET Speaker0 Alright. Welcome, everyone, to twenty twenty five Jefferies Global Healthcare Conference. My name is Roger Song, one of the senior that covers SMICHA biotech at Jefferies, in The US. It's my pleasure to have the next fireside chat with entire pharma CEO Sanjay. Good afternoon, Sanjay. Speaker1 Hi, Roger. How are you? Speaker0 Very good. Alright. So, why not we just get right in, into your lead program, for the pulmonary sarcoidosis? I kno ...
aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)
GlobeNewswire News Room· 2025-06-04 20:00
Three out of four efzofitimod-treated diffuse SSc-ILD patients showed clinically important improvement based on the modified Rodnan Skin Score (mRSS) assessment at 12 weeks. Efzofitimod was generally safe and well tolerated at all doses. SAN DIEGO, June 04, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in- class medicines from its proprietary tRNA synthetase platform, today announc ...
aTyr Pharma (ATYR) Conference Transcript
2025-05-22 00:00
纪要涉及的行业和公司 - 行业:生物科技、医疗健康 [1] - 公司:Atyre Pharma 纪要提到的核心观点和论据 公司定位与核心项目 - 公司是领先的间质性肺病公司,核心项目epsofitimod针对肺结节病的3期试验即将在明年季度出结果,该疗法可能是70年来首个治疗结节病的疗法 [4] 产品研发历程与依据 - 2017年在培养皿中发现Efsulfiramate能调节髓样细胞,后在多种肺损伤动物模型中显示出一致的抗炎效果,锁定结节病为适应症后发现其与神经纤毛蛋白2结合,2期数据表现出色,为推进项目提供信心 [6][7][8][9] 临床数据与分析 - 2期数据显示,药物能改善肺功能、咳嗽、疲劳、气短等症状,同时减少类固醇使用,且呈剂量响应关系;在新的实验模型中,两个最高剂量抑制肉芽肿形成,汇总分析显示更高剂量的药物对肺功能改善更好,相关研究已发表 [12][13] FDA沟通与试验设计调整 - 试验主要终点为类固醇减少,FDA建议在试验最后一个月评估类固醇减少情况,这一调整降低了试验变异性,提高了统计显著性的把握度,降低了成功门槛,对投资者是积极信号 [18][19] 患者基线特征 - 本次试验涉及90个中心、9个国家,患者平均类固醇剂量为10.5mg,标准差较窄,背景免疫调节剂使用情况与上一次试验相近,排除了纤维化患者,患者群体与2期试验具有可比性,为试验结果提供信心 [30][31][32][33][34] 商业潜力 - 新的流行病学研究表明,美国结节病患者中类固醇依赖人群从40 - 50%上升到75%,市场潜力增加30 - 50%,该疗法峰值潜力可能达到50.6亿美元甚至更高 [44][45][46] 其他适应症探索 - 即将公布硬皮病ILD的8例患者皮肤活检数据,虽对结节病肺部读数无直接影响,但可能为药物进入全身性疾病提供机制数据和潜在标签扩展机会 [50][51][52] 公司管线进展 - 新的IND项目在呼吸创新峰会上亮相,该项目通过tRNA合成酶片段诱导肌成纤维细胞凋亡,有望逆转纤维化损伤,公司计划推进其在IPF领域的研究 [58][59][60] 其他重要但可能被忽略的内容 - 公司是数据驱动型公司,注重研究成果的发表,在多个知名期刊上发表了研究成果 [12][14] - 本次3期试验是首个全球多中心试验,在难以招募患者的情况下,公司成功在两年内完成招募,是一项重大成就 [37][38] - 公司正在与欧洲呼吸学会协商,希望在9月的会议上获得展示机会 [42]
aTyr Pharma to Present at Upcoming Investor Conferences
Globenewswire· 2025-05-20 20:00
In addition to the presentations, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the RBC and Jefferies conferences. A webcast of the RBC and Jefferies events will be available on the Investor's section of the company's website at www.atyrpharma.com. Following the events, a replay of the RBC and Jefferies presentations will be available on the aTyr website for at least 90 days. For more information, contact investorrelations@atyrpharm ...
aTyr Pharma, Inc.(ATYR) - 2025 Q1 - Quarterly Report
2025-05-08 04:07
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...
aTyr Pharma, Inc.(ATYR) - 2025 Q1 - Quarterly Results
2025-05-08 04:03
Exhibit 99.1 IMMEDIATE RELEASE Contact: Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be present ...
aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
Globenewswire· 2025-05-08 04:01
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. Blinded baseline demographics and disease characteristics from Phase 3 EFZO-FIT™ study and current U.S. epidemiology and treatment practices for pulmonary sarcoidosis to be presented at ATS 2025. SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-i ...
aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
GlobeNewswire News Room· 2025-04-29 20:00
Title: Immunosuppressive myeloid cells can be modulated with NRP2-targeting antibody ATYR2810 leading to enhanced anti-tumor immunity Authors: Christoph Burkart, Clara Polizzi, John Choi, Max Pastenes, Alison Barber, Michael Lim, Leslie Nangle. aTyr Pharma, San Diego. Department of Neurosurgery, Stanford School of Medicine, Stanford. Session: Antibodies and Antibody-Drug Conjugates Poster Number: 27 Date and Time: Tuesday, April 29, 2025 from 9:00AM – 12:00PM CT Location: Poster Board Section 36, McCormick ...